Montelukast vs. Inhaled Low-Dose Budesonide as Monotherapy in the Treatment of Mild Persistent Asthma: A Randomized Double Blind Controlled Trial
|
|
- Roland Lucas
- 5 years ago
- Views:
Transcription
1 Montelukast vs. Inhaled Low-Dose Budesonide as Monotherapy in the Treatment of Mild Persistent Asthma: A Randomized Double Blind Controlled Trial by Vikram Kumar, a P. Ramesh, a Rakesh Lodha, a R. M. Pandey, b and S. K. Kabra a Departments of a Pediatrics and b Department of Biostatistics, AIIMS, Ansari Nagar, New Delhi Summary Background: Guidelines recommend daily controller therapy for mild persistent asthma. Montelukast has demonstrated consistent benefit in controlling symptoms of asthma and may be an alternative, orally administered, nonsteroidal agent for treating mild asthma. Aim: To determine whether montelukast is as effective as budesonide in controlling mild persistent asthma as determined by FEV 1. Methods: Between November 2003 to October 2005, participants aged 5 15 years with recently diagnosed mild persistent asthma (n ¼ 62) were randomized to oral montelukast (5 mg daily) [N 1 ¼ 30] or inhaled budesonide (400 kg per day in two doses) [N 2 ¼ 32] in a single center, double-blind study. Results: Baseline demographic and spirometric parameters were comparable. The median (95% confidence interval) percentage predicted FEV 1 was similar in the two groups after 12 weeks of treatment (budesonide: ( %), montelukast: 75 ( )%; p ¼ 0.44). There was similar improvement in spirometric parameters and clinical symptom scores in both the groups. There was no statistically significant difference between the groups in the need for rescue drugs as well as side effects reported by parents. Conclusion: Montelukast is as effective as inhaled budesonide in the treatment of mild persistent asthma in children aged 5 15 years. Montelukast may be used as an alternative to low dose inhaled corticosteroids for management of mild persistent asthma. Key words: mild persistent asthma, montelukast, budesonide. Introduction Asthma is the most common chronic illness of childhood in developed as well as developing countries. [1 3] The basic pathophysiology of asthma consist of chronic inflammation of airways. Cysteinyl leukotrienes are inflammatory bioactive lipids produced by various cells. They are present in increased amounts in airway secretions of all different asthma phenotypes and can induce all the inflammatory changes observed in the airways of asthmatic patients. For this reason, an attempt to inhibit the actions of these mediators through the use of cysteinyl receptor antagonists appears rational [4]. Montelukast (MK-0476) is an orally administered potent, specific antagonist of leukotriene receptors [5, 6] that is approved for use in asthma. In adult studies, montelukast (10 mg once daily at bedtime) demonstrated improvement in parameters of asthma control, including forced expiratory volume in 1 s (FEV 1 ), daytime and night-time symptom scores, and as-needed b-agonist use [7, 8]. However, there is limited literature on comparison of montelukast and inhaled corticosteroids (ICS) in mild persistent asthma in children [9 11]. Therefore we compared efficacy of montelukast and ICS in management of mild persistent asthma in children between 5 and 15 years age. Methods This randomized double blind controlled trial was carried out in Pediatric Chest Clinic of All India Institute of Medical Sciences, a tertiary care hospital in New Delhi, India between November 2003 and October Correspondence: Dr S. K. Kabra, Additional Professor, Department of Pediatrics, All India Institute of Medical Sciences, Ansari Nagar, New Delhi <skkabra@hotmail.com>. Participants Children between the ages of 5 and 15 years of either sex with recently diagnosed mild persistent asthma were subjects of the study. Mild persistent asthma ß The Author [2007]. Published by Oxford University Press. All rights reserved. For Permissions, please journals.permissions@oxfordjournals.org 325 doi: /tropej/fmm038
2 was defined as asthma symptoms occurring more than two times in a week but <1 episode per day and exacerbation may affect activity, night time symptoms more than two times a month and peak expiratory flow rate (PEFR) more than or equal to 80% of the predicted [1]. Children with any other chronic illness like tuberculosis, cystic fibrosis; children unable to use inhaler with spacer/to perform spirometry were excluded. Intervention. Patients were randomized to receive either budesonide metered dose inhaler (MDI) (400 mg per day in two doses) þ placebo tablets or montelukast tablets þ placebo MDI. Other supportive care was continued as per standard guideline [1]. Evaluation. Detailed demographic profile and baseline investigations of the subjects were obtained. Spirometry was done using a portable Spiro meter (Cosmed Pony) after properly explaining the correct method to the subjects. The best of three spirometry attempts was recorded. The absolute and percentage predicted values of PEFR, FEV 1, FVC, FEF-25, FEF-50 and FEF-75 were recorded. After recording these parameters, patients were given the drugs for next 1 month, which included one MDI and one pack of 30 tablets. Spacers were used for delivery of drug/ placebo from the MDI. Parents were explained to maintain daily symptom diary, need for rescue drug, any adverse side effects and visit to emergency or local practitioner. Children were followed up every 4 weeks for 12 weeks. Physical examination and spirometry was repeated on each follow-up visit and recorded in a performa. Laboratory tests (hematology, radiology) were obtained at the pre-study visit. Objectives The study was conducted to compare the efficacy of montelukast and ICS in management of mild persistent asthma in children between 5 and 15 years of age. Outcome variables. The change in FEV 1 was the pre-specified primary end point. The change in percentage FEV 1 was compared between the two groups. Other pre-specified end points were mean symptom score for cough, wheezing and sneezing; need for rescue drug with details of drug dosage and duration; symptom free days and side effects. Sample size. A convenient sample size of 60 patients was decided, 30 in each group, as at the time of initiation of this study, there were no similar pediatric studies published. Randomization and blinding. Randomization was done by computer generated simple randomization. For purpose of blinding, similar looking MDIs of budesonide (200 mg per actuation) or placebo and tablets of montelukast (5 mg) or placebo were used. Packets of drugs for each patient were labeled according to randomization sequence by a person not involved in initial or subsequent assessment of the patients. Statistical methods Categorical variables were summarized by frequency (%). Pearson chi-square test was used to compare proportions between the two treatment groups. Comparison of the two groups at baseline and thereafter at each follow-up visit was done. Comparison of various parameters at each follow-up visit with values at the baseline within each group was also done. Continuous variables were summarized by median and 95% confidence intervals. Mann Whitney (Wilcoxon ranksum) test was used to evaluate the differences between the groups. Wilcoxon signed-rank test was used for evaluating the differences in various continuous variables at different times. STATA 7.0 software was used for analysis. Safety and ethical issues Written permission was taken from Drug Controller General of India (DCGI) to conduct the study. The study protocol was approved by the Ethics Committee of AIIMS. A written informed consent was obtained from the parents/legal guardians of study participants. Results From November 2003 to October 2005, 62 children of either sex between the ages of 5 15 years with mild persistent asthma were enrolled in the study. Thirtytwo patients were randomized to receive budesonide (400 mg per day in two doses) from an MDI and placebo tablets. Thirty patients were randomized to receive montelukast tablets and placebo MDI. Four children were lost to follow up, three from montelukast group and one from budesonide group. Two patients, one from each group, were taken out of the study as they had developed skin rashes after few days of starting therapy (Fig. 1). The two groups were comparable in their baseline characteristics except for age and height (Table 1). There was no statistically significant difference in the treatment received in the form of oral bronchodilators, inhaled bronchodilators and theophylline. It was noted that four patients in montelukast group were on ICS for a period of less than 1 week prior to the enrollment in the study and there were none in the budesonide group. The groups were comparable in the baseline spirometric parameters except for FEV 1 and FEF- 75. The mean FEV 1 in group A was 1.4 l and in group 326 Journal of Tropical Pediatrics Vol. 53, No. 5
3 New patients with asthma attended Pediatric chest clinic during study period 760 Mild persistent asthma: 80 Patients enrolled: 62 Moderate persistent asthma Severe persistent asthma Already on inhaled steroids: 12 Staying far off (not possible to follow up): 6 FIG. 1. Trial profile. 1: lost to follow up 1: withdrawn because of rashes Group A Budesonide: 32 B was 1.13 l (95% CI ¼ ) (p ¼ 0.03). It persisted at second follow-up visit at 2 months (p ¼ 0.006). However, there was no statistical difference of change in FEV 1 from baseline to the end of the study in either group (Table 2). On comparing the change in percentage predicted FEV 1 from baseline to end of study within the groups, there was improvement in both the groups but it was not statistically significant. There was also no statistically significant difference in percentage Group B Budesonide: 30 3: lost to follow up 1: withdrawn because of rashes Total completed: 30 Total completed: 26 TABLE 1 Comparison of baseline parameters Budesonide group (n ¼ 32) Montelukast group (n ¼ 30) p-value Age (year) (mean SD) c Sex (M/F) 25/7 25/ b Cough b Wheeze b Sneezing b Weight (kg) (median) a Height (cm) (median) a Hb (g dl 1 ) 9.9 ( ) 10.1( ) 0.31 a Eosinophils (%) 1 (0 2) 2 (0 3) 0.68 a PEFR (l s 1 ) 2.84 ( ) 2.34 ( ) 0.47 a FEV-1 (l) 1.4 ( ) 1.13 ( ) 0.03 a FEV 1 (% predicted) 76 ( ) 73.5 ( ) 0.64 a FEF-25 (l s 1 ) 2.44 ( ) 1.99 ( ) 0.23 a FEF-50 (l s 1 ) 2.09 ( ) 1.48 ( ) 0.16 a FEF-75 (l s 1 ) 1.45 ( ) 1.26 ( ) 0.70 a FVC (l) 1.55 ( ) 1.24 ( ) 0.08 a a Mann Whitney test; b chi-square; c t-test. Values for spirometric parameters are median (95% CI). predicted FEV 1 between the two groups at the end of the study (Fig. 2). PEFR. On comparing the absolute values of PEFR in the two groups there was an improvement in values: 2.84 l s 1 (95% CI ¼ ) at baseline to 3.04 l s 1 (95% CI ¼ ) at end of study in children getting budesonide and from 2.34 l s 1 (95% CI ¼ ) to 2.74 l s 1 (95% CI ¼ ) in children getting montelukast. Journal of Tropical Pediatrics Vol. 53, No
4 TABLE 2 Changes in FEV 1 on follow up Budesonide group Montelukast group p-value a FEV 1 (L) baseline 1.4 ( ) (n ¼ 32) 1.13 ( ) (n ¼ 30) 0.03 FEV 1 (L) at 1 month 1.39 ( ) p ¼ 0.56 b (n ¼ 30) 1.11 ( ) p b ¼0.76 (n ¼ 26) 0.07 FEV 1 (L) at 2 months 1.48 ( ) p ¼ 0.11 b (n ¼ 30) 1.18 ( ) p ¼ 0.98 b (n ¼ 26) FEV 1 (L) at 3 months 1.44 ( ) p ¼ 0.17 b (n ¼ 30) 1.26 ( ) p ¼ 0.30 b (n ¼ 26) 0.08 Percentage a Comparing the values between montelukast and budesonide groups (Mann whitney test). b Comparing the values within the same group with the baseline value (Wilcoxan signed rank test). Values are median (95% CI) Baseline 1 month 2 months 3 months Changes in FEV 1 (percentage predicted) Budesonide group Montelukast group FIG. 2. Changes in FEV 1 (percentage predicted) on follow up. There was no statistical difference in the change of FVC, percentage predicted FVC, change of FEF-25, percentage predicted FEF-25, FEF-50 and percentage predicted FEF-50 from base line to end of study within the two groups and between the two groups. Trend towards improvement was observed in both the groups. Secondary outcome variables There was no statistically significant difference in the average symptom score and symptom free days for cough, wheeze, sneezing in either group from the baseline to the end of the study. Two children in the budesonide group required inhaled salbutamol for cumulative of 24 days; four children in the montelukast group required inhaled salbutamol for cumulative of 30 days. These differences were not statistically significant. None required any oral steroids. Two patients, one in each group had developed skin rashes. Two patients in budesonide group reported sedation. There was no other side effect reported during the study in either group. Discussion This study suggests that montelukast and low-dose inhaled budesonide are comparable in the treatment of mild persistent asthma in children between 5 and 15 years of age over a period of 3 months. The baseline parameters were comparable in two groups except difference in age and height. The influences of these differences on the differences in the spirometric parameters were taken care of by comparing the percentage predicted values for the spirometric parameters between the two groups. Most of the studies in published literature on montelukast in childhood asthma had compared montelukast with placebo and found that oral montelukast (4 mg chewable tablet) administered once daily is effective therapy for asthma in children aged 2 5 years and is generally well-tolerated without clinically important adverse effects [12, 13]. Similarly, in adults and children aged 6 14 years, montelukast improved multiple parameters of asthma control, and was also effective in reducing markers of chronic inflammation [14, 15]. Studies comparing montelukast and ICS reported conflicting results. A recently published multicenter 12-month noninferiority trial [16] compared montelukast with inhaled fluticasone to assess the increase in the percentage of RFDs (rescue-free days) among 996 children between 6 and 14 years of age with mild persistent asthma. The difference in RFDs between montelukast and fluticasone was <1 day per month. Secondary end points, including percentage of predicted forced expiratory volume in 1 s value, days with ß-receptor agonist use and quality of life, improved in both groups but were significantly better in the fluticasone treatment group. However, patient and parent satisfaction, convenience and adherence to treatment were better with montelukast than ICS. In a similar 12-month parallel-group multicenter study [17] looking at RFDs as a composite clinical marker of the efficacy of control of mild persistent asthma in participants aged years with mild persistent asthma, oral montelukast (10 mg once nightly) was comparable to inhaled fluticasone (88 mg twice daily) Ostrom et al. [18] reported superiority of fluticosone over montelukast in their randomized, double-blind, 12-week study on 342 children 328 Journal of Tropical Pediatrics Vol. 53, No. 5
5 (6 12 years of age) in improvement in FEV 1, PEFR, and percent rescue-free days, night-time symptom scores and mean salbutamol use. Adverse events (69% vs. 71%) were similar. Parents and physicians were more satisfied with fluticasone treatment than with montelukast. The contradictory results of these studies may be because of differences in the patient populations and duration of study. However, in both the studies, the ICS group had better improvement in the spirometric parameters. In our study we found that montelukast was as effective as ICS in improving lung function end points such as peak flow and forced expiratory volume in 1 s (FEV 1 ). The results of our study are also similar to results from a 6-month, open-label trial comparing montelukast with beclomethasone among 6 11 year-old children by Becker et al. [19]. In this study, montelukast and beclomethasone provided equivalent protection with respect to asthmarelated resource utilization, as well as other clinical end points. Knorr et al. [20] found that montelukast demonstrated a consistent effect regardless of concomitant use of inhaled/nebulized corticosteroid or cromolyn therapy. Both montelukast and budesonide were generally well-tolerated. Drug-related adverse experiences occurred in <5% of patients in both the montelukast and budesonide groups; the most commonly reported experiences were skin rash and sedation. This result was comparable with two recent studies. Knorr et al. [20] had concluded that montelukast was welltolerated and efficacious in children with mild persistent asthma. Another study conducted by Van et al. [21] concluded that montelukast was safe over a period of 6 weeks. The major limitation of the present study included small sample size and follow up was for only 3 months. It would have been desirable to have a runin drug-free period of about 2 4 weeks to evaluate the symptom scores and symptom free days. In summary, this study demonstrated that montelukast once daily is as effective a therapy as low dose ICS in 5 15-year-old patients with mild persistent asthma. Montelukast was welltolerated and demonstrated a safety profile similar to ICS. References 1. National Asthma Education and Prevention Program. Expert Panel Report II: Guidelines for the Diagnosis and Management of Asthma: NHLBI Workshop Report. Bethesda, MD: National Heart, Lung, and Blood Institute, National Institutes of Health, Ducharame FM, Davis GM. Randomized controlled trial of ipratropium bromide and frequent low doses of salbutamol in management of asthma. J Pediatrics 1998;133: Gergen PJ, Weiss KB. Changing patterns of asthma hospitalization among children: 1979 to JAMA 1990;264: Capristo C, Rigotti E, Boner AL. Update on the use of montelukast in pediatric asthma. Allergy Asthma Proc 2006;27: Noonan MJ, Chervinsky P, Brandon M, et al. Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Montelukast Asthma Study Group. Eur Respir J 1998;11: Reiss TF, Chervinsky P, Dockhorn RJ, et al. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med 1998;158: Reiss TF, Altman LC, Chervinsky P, et al. Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma. J Allergy Clin Immunol 1996;98: Altman LC, Munk Z, Seltzer J, et al. A placebocontrolled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. Montelukast Asthma Study Group. J allergy Clin Immunol 1998;102: Busse W, Raphael GD, Galant S, et al. Fluticasone Proprionate Clinical Research Study Group. Low-dose fluticasone proprionate compared with montelukast for first-line treatment of persistent asthma: a randomized clinical trial. J Allergy Clin Immunol 2001;107: Calhoun WJ, Nelson HS, Nathan RA, et al. Comparison of fluticasone propionate salmeterol combination therapy and montelukast in patients who are symptomatic on short-acting b2-agonists alone. Am J Respir Crit Care Med 2001;164: Sorkness CA, Lemanske RF, Jr, Mauger DT, et al. For the Childhood Asthma Research and Education Network of the National Heart, Lung, and Blood Institute. Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the pediatric asthma controller trial. J Allergy Clin Immunol 2007;119: Knorr B, Franchi LM, Bisgaard H, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001;108:e Muijsers RB, Noble S. Montelukast: a review of its therapeutic potential in asthma in children 2 to 14 years of age. Paediatr Drugs 2002;4: Warner JO. The role of leukotriene receptor antagonists in the treatment of chronic asthma in childhood. Allergy 2001;56 (Suppl 66): Kanniess F, Richter K, Bo hme S, et al. Montelukast versus fluticasone: effects on lung function, airway responsiveness and inflammation in moderate asthma. Eur Respir J 2002;20: Garcia Garcia ML, Wahn U, Gilles L, et al. Montelukast compared with fluticasone, for control of asthma among 6- to 14-year-old patients with mild asthma: the MOSAIC study. Pediatrics 2005;116: Journal of Tropical Pediatrics Vol. 53, No
6 17. Zeiger RS, Bird SR, Kaplan MS, et al. Short-term and long-term asthma control in patients with mild persistent asthma receiving montelukast or fluticasone: a randomized controlled trial. Am J Med 2005;118: Ostrom NK, Decotiis BA, Lincourt WR, et al. Comparative efficacy and safety of low-dose fluticasone propionate and montelukast in children with persistent asthma. J Pediatr 2005;147: Becker A, Swern A, Tozzi CA, et al. Montelukast in asthmatic patients 6 years-14 years old with an FEV1 > 75%. Curr Med Res Opin 2004; Knorr B, Matz J, Bernstein JA, et al. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. JAMA 1998;279: van Adelsberg J, Moy J, Wei LX, et al. Safety, tolerability, and exploratory efficacy of montelukast in 6 to 24 month-old patients with asthma. Curr Med Res Opin 2005;21: Journal of Tropical Pediatrics Vol. 53, No. 5
Efficacy and Safety of Montelukast as Monotherapy in Children with Mild Persistent Asthma. Gautam Ghosh, Arun Kumar Manglik and Subhasis Roy
Efficacy and Safety of Montelukast as Monotherapy in Children with Mild Persistent Asthma Gautam Ghosh, Arun Kumar Manglik and Subhasis Roy From the Shree Jain Hospital & Research Center, Howrah 711 102
More informationDual-Controller Asthma Therapy: Rationale and Clinical Benefits
B/1 Dual-Controller Asthma Therapy: Rationale and Clinical Benefits MODULE B The 1997 National Heart, Lung, and Blood Institute (NHLBI) Expert Panel guidelines on asthma management recommend a 4-step approach
More informationClinical trial efficacy: What does it really tell you?
Clinical trial efficacy: What does it really tell you? Joseph Spahn, MD Denver, Colo The primary goal of most clinical trials is an evaluation of the efficacy of the drug being evaluated. Therefore, it
More informationManagement of asthma in preschool children with inhaled corticosteroids and leukotriene receptor antagonists Leonard B. Bacharier
Management of asthma in preschool children with inhaled corticosteroids and leukotriene receptor antagonists Leonard B. Bacharier Department of Pediatrics, Division of Allergy and Pulmonary Medicine, Washington
More informationGuideline topic: Pharmacological management of asthma Evidence table 4.4d: Leukotriene receptor antagonists with short-acting betaagonists
1 of 5 09/05/2018, 11:12 Guideline topic: Pharmacological management of asthma Evidence table 4.4d: Leukotriene receptor antagonists with short-acting betaagonists Author Year Study type Quality rating
More informationDual-controller therapy, or combinations REVIEW DUAL-CONTROLLER REGIMENS I: DATA FROM RANDOMIZED, CONTROLLED CLINICAL TRIALS.
DUAL-CONTROLLER REGIMENS I: DATA FROM RANDOMIZED, CONTROLLED CLINICAL TRIALS Samy Suissa, PhD ABSTRACT Dual-controller therapy, or combinations of 2 or more pharmacotherapies with complementary mechanisms
More informationInternational Journal of Medical Research & Health Sciences
International Journal of Medical Research & Health Sciences www.ijmrhs.com Volume 2 Issue 3 July - Sep Coden: IJMRHS Copyright @2013 ISSN: 2319-5886 Received: 23 th May 2013 Revised: 24 th Jun 2013 Accepted:
More informationTips on managing asthma in children
Tips on managing asthma in children Dr Ranjan Suri Consultant in Respiratory Paediatrics Bupa Cromwell Hospital Clinics: Friday (pm) Asthma in Children Making the diagnosis Patterns of childhood asthma
More informationPredicting, Preventing and Managing Asthma Exacerbations. Heather Zar Department of Paediatrics & Child Health University of Cape Town South Africa
Predicting, Preventing and Managing Asthma Exacerbations Heather Zar Department of Paediatrics & Child Health University of Cape Town South Africa Asthma exacerbations Predicting exacerbation recognising
More informationViral-Induced Asthma:
Viral-Induced : Sorting through the Studies Malcolm R. Sears, MB, FRACP, FRCPC Presented at the Respirology Update Continuing Education Program, January 2005 Viral-associated wheezing is common and not
More informationAsthma training. Mike Levin Division of Asthma and Allergy Red Cross Hospital
Asthma training Mike Levin Division of Asthma and Allergy Red Cross Hospital Introduction Physiology Diagnosis Severity Treatment Control Stage 3 of guidelines Acute asthma Drug delivery Conclusion Overview
More informationBudesonide treatment of moderate and severe asthma in children: A doseresponse
Budesonide treatment of moderate and severe asthma in children: A doseresponse study Soren Pedersen, MD, PhD, and Ove Ramsgaard Hansen, MD Kolding, Denmark Objective: The purpose of the study was to evaluate
More informationLeukotriene receptor antagonists in the management of childhood asthma
Information Paper paper for health Health professionals Professionals LTRAs for childhood asthma Leukotriene receptor antagonists in the management of childhood asthma Key points Introduction This information
More informationJames P. Kemp, MD; Margaret C. Minkwitz, PhD; Catherine M. Bonuccelli, MD; and Marshelle S. Warren, MD
Therapeutic Effect of Zafirlukast as Monotherapy in Steroid-Naive Patients With Severe Persistent Asthma* James P. Kemp, MD; Margaret C. Minkwitz, PhD; Catherine M. Bonuccelli, MD; and Marshelle S. Warren,
More informationStep-down approach in chronic stable asthma: A comparison of reducing dose Inhaled Formoterol/ Budesonide with maintaining Inhaled Budesonide.
Step-down approach in chronic stable asthma: A comparison of reducing dose Inhaled Formoterol/ Budesonide with maintaining Inhaled Budesonide. By: DR MOHD SHAMSUL AMRI Supervisor: Associate Professor Dr
More informationDiagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma
Diagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma Magnitude of Asthma - India Delhi Childhood asthma: 10.9% Adults: 8% Other Cities 3 to 18% Chhabra SK et al Ann Allergy Asthma
More informationClinical efficacy of montelukast in anti-inflammatory treatment of asthma and allergic rhinitis
Clinical efficacy of montelukast in anti-inflammatory treatment of asthma and allergic rhinitis Kim Hyun Hee, MD, PhD. Dept. of Pediatrics The Catholic University of Korea College of Medicine Achieving
More informationSYNOPSIS THIS IS A PRINTED COPY OF AN ELECTRONIC DOCUMENT. PLEASE CHECK ITS VALIDITY BEFORE USE.
Drug product: Drug substance(s): Document No.: Edition No.: 1 Study code: Accolate Zafirlukast (ZD9188) 9188IL/0138 Date: 02 May 2007 SYNOPSIS A Multicenter, Randomized, Double-blind, -controlled, Parallel
More informationPathophysiology of the cysteinyl leukotrienes and effects of leukotriene receptor antagonists in asthma
Allergy 2001: 56: Suppl. 66: 7 11 Printed in UK. All rights reserved Copyright # Munksgaard 2001 ALLERGY ISSN 0108-1675 Pathophysiology of the cysteinyl leukotrienes and effects of leukotriene receptor
More information12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationLearning the Asthma Guidelines by Case Studies
Learning the Asthma Guidelines by Case Studies Timothy Craig, DO Professor of Medicine and Pediatrics Distinguished Educator Penn State University Hershey Medical Center Objectives 1. Learn the Asthma
More informationDaclizumab improves asthma control in patients with moderate to. severe persistent asthma: A randomized, controlled trial
Daclizumab improves asthma control in patients with moderate to severe persistent asthma: A randomized, controlled trial William W. Busse, MD, Elliot Israel, MD, Harold S. Nelson, MD, James W. Baker, MD,
More informationMODERATE PERSISTENT ASTHMA IN CHILDREN; COMPARISON OF INHALED BECLOMETHASONE WITH ORAL MONTELUKAST IN THE MANAGEMENT
The Professional Medical Journal www.theprofesional.com ORIGINAL PROF-2495 MODERATE PERSISTENT ASTHMA IN CHILDREN; COMPARISON OF INHALED BECLOMETHASONE WITH ORAL MONTELUKAST IN THE MANAGEMENT 1 2 3 Dr.
More informationAsthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationDR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL
DR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL Definition Guidelines contact complicated definitions Central to this is Presence of symptoms Variable airflow obstruction Diagnosis
More informationChildhood Asthma. The pathophysiology of asthma is an interplay. CME Case Study. Case Study. By Moyez B. Ladhani, MD, CCFP, FAAP, FRCPC
CME Case Study Childhood Asthma By Moyez B. Ladhani, MD, CCFP, FAAP, FRCPC Case Study A two-year-old child presents to your office with a cough, which has been present for three weeks. It is worse at nighttime
More informationMeenu Singh, Joseph L. Mathew, Prabhjot Malhi, B.R. Srinivas and Lata Kumar
Comparison of Improvement in Quality of Life Score with Objective Parameters of Pulmonary Function in Indian Asthmatic Children Receiving Inhaled Corticosteroid Therapy Meenu Singh, Joseph L. Mathew, Prabhjot
More informationTitle: Leukotriene Receptor Antagonist (LTRA) for Asthma. Date: April 12, 2007
Title: Leukotriene Receptor Antagonist (LTRA) for Asthma Date: April 12, 2007 Context and policy issues: Asthma is a chronic airways condition with symptoms varying from person to person and episode to
More informationDistribution of therapeutic response in asthma control between oral montelukast and inhaled beclomethasone
Eur Respir J 2003; 21: 123 128 DOI: 10.1183/09031936.03.00028803 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2003 European Respiratory Journal ISSN 0903-1936 Distribution of therapeutic
More informationOmalizumab (Xolair ) ( Genentech, Inc., Novartis Pharmaceuticals Corp.) September Indication
( Genentech, Inc., Novartis Pharmaceuticals Corp.) September 2003 Indication The FDA recently approved Omalizumab on June 20, 2003 for adults and adolescents (12 years of age and above) with moderate to
More informationControversial Issues in the Management of Childhood Asthma: Insights from NIH Asthma Network Studies
Controversial Issues in the Management of Childhood Asthma: Insights from NIH Asthma Network Studies Stanley J. Szefler, MD Helen Wohlberg and Herman Lambert Chair in Pharmacokinetics, Head, Pediatric
More informationLack of tolerance to the protective effect of montelukast in exercise-induced bronchoconstriction in children
Eur Respir J 2006; 28: 291 295 DOI: 10.1183/09031936.06.00020606 CopyrightßERS Journals Ltd 2006 Lack of tolerance to the protective effect of montelukast in exercise-induced bronchoconstriction in children
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationQ: Should patients with mild asthma
1-MINUTE CONSULT CME CREDIT EDUCATIONAL OBJECTIVE: Readers will consider prescribing inhaled corticosteroids to their patients who have mild persistent asthma brief answers to specific clinical questions
More informationScottish Medicines Consortium
Scottish Medicines Consortium montelukast 10mg tablets (Singulair ) No. (185/05) Merck, Sharp & Dohme Ltd (MSD) New indication: for asthmatic patients in whom montelukast is indicated in asthma, montelukast
More informationInterventions to improve adherence to inhaled steroids for asthma. Respiratory department
Interventions to improve adherence to inhaled steroids for asthma Respiratory department Content Overview Research References Overview Asthma is a chronic breathing condition that affects more than 300
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSHORT COMMUNICATION. Abstract. Kevin R. Murphy, 1 Tom Uryniak, 2 Ubaldo J. Martin 2 and James Zangrilli 2
SHORT COMMUNICATION Drugs R D 212; 12 (1): 9-14 1179-691/12/1-9 ª 212 Murphy et al., publisher and licensee Adis Data Information BV. This is an open access article published under the terms of the Creative
More information#1 cause of school absenteeism in children 13 million missed days annually
Asthma Update 2013 Jennifer W. McCallister, MD, FACP, FCCP Associate Professor Pulmonary & Critical Care Medicine The Ohio State University Wexner Medical Center Disclosures None 2 Objectives Review burden
More informationBUDESONIDE AND FORMOTEROL (SYMBICORT ): Α A REVIEW
Volume 23, Issue 3 December 2007 BUDESONIDE AND FORMOTEROL (SYMBICORT ): A REVIEW Donna L. Smith, Pharm. D. Candidate More than 22 million people in the United States have asthma according to the Centers
More informationSafety and Tolerability of Montelukast in Placebo-Controlled Pediatric Studies and Their Open-Label Extensions
44:568 579 (2009) Safety and Tolerability of Montelukast in -Controlled Pediatric Studies and Their Open-Label Extensions Hans Bisgaard, MD, DMSci, 1 * David Skoner, MD, 2 Maria L. Boza, MD, 3 Carol A.
More informationII: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical
Table 3.1. Classification of COPD Severity Stage Pulmonary Function Test Findings Symptoms I: Mild Mild airflow limitations +/ Chronic cough and sputum production; patient unaware of abnormal FEV 1 80%
More informationAlthough elucidation of the basic physiologic
Salmeterol Powder Provides Significantly Better Benefit Than Montelukast in Asthmatic Patients Receiving Concomitant Inhaled Corticosteroid Therapy* James E. Fish, MD, FCCP; Elliot Israel, MD, FCCP; John
More informationType of intervention Treatment. Economic study type Cost-effectiveness analysis.
Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 micro g twice daily and budesonide 800 micro g twice daily in the treatment of adults and adolescents with asthma Lundback
More informationDiagnosis and Management of Asthma in Children based on the British Thoracic Society and Scottish Intercollegiate Guidelines Network September 2016
Diagnosis and Management of Asthma in Children based on the British Thoracic Society and Scottish Intercollegiate Guidelines Network September 2016 Diagnosis: There is no lower limit to the age at which
More informationAsthma in Pregnancy. Asthma. Chronic Airway Inflammation. Objective Measures of Airflow. Peak exp. flow rate (PEFR)
Chronic Airway Inflammation Asthma in Pregnancy Robin Field, MD Maternal Fetal Medicine Kaiser Permanente San Francisco Asthma Chronic airway inflammation increased airway responsiveness to a variety of
More informationFour of 10 patients with asthma suffer moderate REVIEW DUAL-CONTROLLER REGIMENS II: OBSERVATIONAL DATA. Michael S. Blaiss, MD ABSTRACT
DUAL-CONTROLLER REGIMENS II: OBSERVATIONAL DATA Michael S. Blaiss, MD ABSTRACT The differences between clinical trials and clinical practice often create difficulty for generalizing results of controlled
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationG. Boyd on behalf of a UK Study group
Eur Respir J, 1995, 8, 1494 1498 DOI: 10.1183/09031936.95.08091494 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1995 European Respiratory Journal ISSN 0903-1936 Salmeterol xinafoate in
More informationPotency ratio fluticasone propionate (Flixotide Diskus)/budesonide (Pulmicort Turbuhaler)
Respiratory Medicine (2007) 101, 610 615 Potency ratio fluticasone propionate (Flixotide Diskus)/budesonide (Pulmicort Turbuhaler) Björn Ställberg a, Eva Pilman b, Bengt-Eric Skoogh c,, Bengt Arne Hermansson
More informationOn completion of this chapter you should be able to: discuss the stepwise approach to the pharmacological management of asthma in children
7 Asthma Asthma is a common disease in children and its incidence has been increasing in recent years. Between 10-15% of children have been diagnosed with asthma. It is therefore a condition that pharmacists
More informationGINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017
GINA At-A-Glance Asthma Management Reference for adults, adolescents and children 6 11 years Updated 2017 This resource should be used in conjunction with the Global Strategy for Asthma Management and
More informationPractical Approach to Managing Paediatric Asthma
Practical Approach to Managing Paediatric Asthma Dr Andrew Tai FRACP, PhD Paediatric Respiratory and Sleep Specialist Women's and Children's Hospital, Adelaide Approaching the patient Check the diagnosis
More informationAbstract Background Theophylline is widely used in the treatment of asthma, and there is evidence that theophylline has antiinflammatory
Thorax 2000;55:837 841 837 National Heart and Lung Institute, Imperial College School of Medicine and Royal Brompton Hospital, London SW3 6LY, UK S Lim A Jatakanon K F Chung P J Barnes Napp Laboratories
More informationThe 3 components of evidence. Economic Analysis of Asthma Practices ...PRESENTATIONS... Based on a presentation by David A.
...PRESENTATIONS... Economic Analysis of Asthma Practices Based on a presentation by David A. Stempel, MD Presentation Summary When deciding on treatment for patients with asthma, clinicians should consider
More informationTreatment of acute asthmatic exacerbations with an increased dose of inhaled steroid
12 Paediatrics and Child Health, Dunedin School of Medicine, PO Box 913, University of Otago Medical School, Dunedin, New Zealand J Garrett Preventive and Social Medicine, Dunedin School of Medicine S
More informationStudy No.: SAM40012 Title: A multicentre, randomised, double-blind, double-dummy, parallel group comparison of three treatments : 1)
Study No.: SAM40012 Title: A multicentre, randomised, double-blind, double-dummy, parallel group comparison of three treatments : 1) salmeterol/fluticasone propionate () (mcg strength) bd via DISKUS/ACCUHALER
More informationFull Length Original Research Paper
Copyright 2013 By IYPF All rights reserved Open Access Contents Int. J. Drug Dev. & Res. October - December 2013 Vol. 5 Issue 4 ISSN 0975-9344 www.ijddr.in Effect of Budesonide by metered dose inhaler
More informationDecramer 2014 a &b [21]
Buhl 2015 [19] Celli 2014 [20] Decramer 2014 a &b [21] D Urzo 2014 [22] Maleki-Yazdi 2014 [23] Inclusion criteria: Diagnosis of chronic obstructive pulmonary disease; 40 years of age or older; Relatively
More informationA comparison of global questions versus health status questionnaires as measures of the severity and impact of asthma
Eur Respir J 1999; 1: 591±596 Printed in UK ± all rights reserved Copyright #ERS Journals Ltd 1999 European Respiratory Journal ISSN 93-1936 A comparison of global questions versus health status questionnaires
More informationThe Acute & Maintenance Treatment of Asthma via Aerosolized Medications
The Acute & Maintenance Treatment of Asthma via Aerosolized Medications Douglas S. Gardenhire, EdD, RRT-NPS, FAARC Associate Professor and Chairman Department of Respiratory Therapy Objectives Define Asthma.
More informationASTHMA. Epidemiology. Pathophysiology. Diagnosis. IAP UG Teaching slides
BRONCHIAL ASTHMA ASTHMA Epidemiology Pathophysiology Diagnosis 2 CHILDHOOD ASTHMA Childhood bronchial asthma is characterized by Airway obstruction which is reversible Airway inflammation Airway hyper
More informationALLERGIC RHINITIS AND ASTHMA :
ALLERGIC RHINITIS AND ASTHMA : from the Link to Emerging Therapies Allergic rhinitis and asthma are both chronic heterogeneous disorders, with an overlapping epidemiology of prevalence, health care costs
More informationAirways hyperresponsiveness to different inhaled combination therapies in adolescent asthmatics
Airways hyperresponsiveness to different inhaled combination therapies in adolescent asthmatics Daniel Machado 1, MD Celso Pereira 1,2, MD, PhD Beatriz Tavares 1, MD Graça Loureiro 1, MD António Segorbe-Luís
More informationSUMMARY THIS IS A PRINTED COPY OF AN ELECTRONIC DOCUMENT. PLEASE CHECK ITS VALIDITY BEFORE USE.
i SUMMARY ZENECA PHARMACEUTICALS FINISHED PRODUCT: ACTIVE INGREDIENT: ACCOLATE zafirlukast (ZD9188) Trial title (number): A Dose-ranging, Safety and Efficacy Trial with Zafirlukast (ACCOLATE ) in the Treatment
More informationChronic obstructive pulmonary disease (COPD) is characterized
DANIEL E. HILLEMAN, PharmD ABSTRACT OBJECTIVE: To review the role of long-acting bronchodilators in the treatment of chronic obstructive pulmonary disease (COPD), including the importance of treatment
More informationIn 2002, it was reported that 72 of 1000
REPORTS Aligning Patient Care and Asthma Treatment Guidelines Eric Cannon, PharmD Abstract This article describes how the National Asthma Education and Prevention Program Guidelines for the Diagnosis and
More informationAsthma for Primary Care: Assessment, Control, and Long-Term Management
Asthma for Primary Care: Assessment, Control, and Long-Term Management Learning Objectives After participating in this educational activity, participants should be better able to: 1. Choose the optimal
More informationAdherence to asthma controller medication regimens
Respiratory Medicine (2005) 99, 1263 1267 Adherence to asthma controller medication regimens D.A. Stempel a,, S.W. Stoloff b, J.R. Carranza Rosenzweig c, R.H. Stanford c, K.L. Ryskina d, A.P. Legorreta
More informationPediatric Asthma: Pharmacotherapy. Joseph Spahn, MD Children s Hospital Colorado & University of Colorado Medical School Aurora, Colorado
Pediatric Asthma: Pharmacotherapy Joseph Spahn, MD Children s Hospital Colorado & University of Colorado Medical School Aurora, Colorado Pediatric Asthma: Pharmacotherapy Disclosures/Conflicts of Interest:
More informationSearching for Targets to Control Asthma
Searching for Targets to Control Asthma Timothy Craig Distinguished Educator Professor Medicine and Pediatrics Penn State University Hershey, PA, USA Inflammation and Remodeling in Asthma The most important
More informationEfficacy and safety of montelukast in adults with asthma and allergic rhinitis
Respiratory Medicine (26), 1952 1959 Efficacy and safety of montelukast in adults with asthma and allergic rhinitis J.Chr. Virchow a,, C. Bachert b a Universität Rostock, Ernst-Heydemann-Str. 6, 1857 Rostock,
More informationGuideline topic: Pharmacological management of asthma Evidence table 4.15: Mometasone Furoate dry powder inhalation evidence
1 of 12 09/05/2018, 11:53 Guideline topic: Pharmacological management of asthma Evidence table 4.15: Mometasone Furoate dry powder inhalation evidence Author Year Study type Quality rating Population Outcomes
More informationRESPIRATORY CARE IN GENERAL PRACTICE
RESPIRATORY CARE IN GENERAL PRACTICE Definitions of Asthma and COPD Asthma is due to inflammation of the air passages in the lungs and affects the sensitivity of the nerve endings in the airways so they
More informationAlternative agents for anti-inflammatory treatment of asthma
Alternative agents for anti-inflammatory treatment of asthma Stanley J. Szefler, MD, a,b and Harold S. Nelson, MD, c Denver, Colo Recent guidelines for the management of asthma have emphasized the role
More informationSupplementary Medications during asthma attack. Prof. Dr Finn Rasmussen PhD. DrMedSc. Near East University Hospital North Cyprus
Supplementary Medications during asthma attack Prof. Dr Finn Rasmussen PhD. DrMedSc. Near East University Hospital North Cyprus Conflicts of Interest None Definition of Asthma Airway narrowing that is
More informationmeasured Improvement in am PEFR FP vs BUD gave +11l/min FP vs BDP gave nonsignificant improvement in PEFR +3l/min FP: BUD ratio 1.
1 of 8 09/05/2018, 11:29 Guideline topic: Pharmacological management of asthma Evidence table 4.25: Budesonide vs Beclomethasone Different inhaled corticosteroids (ICS) flixotide propionate (FP) vs budesonide
More informationCurrent Asthma Management: Opportunities for a Nutrition-Based Intervention
Current Asthma Management: Opportunities for a Nutrition-Based Intervention Stanley J. Szefler, MD Approximately 22 million Americans, including 6 million children, have asthma. It is one of the most prevalent
More informationAsthma Assessment & Review
ASTHMA RESOURCE PACK Section 5B Asthma Assessment & Review In this section: 1. Primary Care initial assessment and review Asthma Resource Pack Section 5B: Asthma Assessment & Review Version 3.0 Last Updated:
More informationInternational Journal of Medical Science and Education pissn eissn
COMPARISON OF MONTELUKAST AND KETOTIFEN AS ADD ON THERAPY IN MODERATE AND SEVERE PERSISTENT BRONCHIAL ASTHMA Dr. Gaurav Chhabra 1, Dr. Shubhakaran Sharma 2* Original research article 1,2 Associate professor,
More informationAsthma: Classification, Management, Prevention and New Treatments
Asthma: Classification, Management, Prevention and New Treatments Cori Daines, MD, Professor Pediatric Pulmonary Medicine University of Arizona April 28, 2018 I have no relevant financial relationships
More informationThe recent guidelines from the
...PRESENTATIONS... Adjunctive Therapy for Asthma: Treatment Options Robert A. Nathan, MD Abstract The National Heart, Lung, and Blood Institute guidelines on the diagnosis and management of asthma recommend
More informationAlberta Childhood Asthma Pathway for Primary Care
Asthma Diagnosis Box 1 Diagnosis: Based on symptom pattern, careful and thorough history of symptoms (wheeze, cough, night waking and activity limitations), and assessment of family history of asthma and
More informationThe ability of peak flow measurement
Lessons Learned From the Asthma Clinical Research Network By Brian Piazza, MS 2 and Timothy J. Craig, DO In 1993, the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health
More informationAvailable online at
Available online at www.annclinlabsci.org 285 Tapering Dose of Inhaled Budesonide in Subjects with Mild-to-Moderate Persistent Asthma Treated with Montelukast: A 16-Week Single-Blind Randomized Study Graziano
More informationAsthma in Pediatric Patients. DanThuy Dao, D.O., FAAP. Disclosures. None
Asthma in Pediatric Patients DanThuy Dao, D.O., FAAP Disclosures None Objectives 1. Discuss the evaluation and management of asthma in a pediatric patient 2. Accurately assess asthma severity and level
More informationASTHMA PRESCRIBING GUIDELINES FOR ADULTS AND CHILDREN OVER 12
North Hampshire CCG Asthma Prescribing Guidelines June 2015 ASTHMA PRESCRIBING GUIDELINES FOR ADULTS AND CHILDREN OVER 12 These guidelines are based on the British Thoracic Society (BTS) and Scottish Intercollegiate
More informationIdentifying and managing the infant and toddler at risk for asthma
Clinical pearls Identifying and managing the infant and toddler at risk for asthma Theresa W. Guilbert, MD Madison, Wis Key words: Infants, children, asthma, wheezing, inhaled corticosteroids, leukotriene
More informationGUIDE LINE SUMMARY THE DIAGNOSIS AND TREATMENT OF ADULT ASTHMA BEST PRACTICE EV I DENCE-BASED KEY MESSAGES. Diagnosis.
THE DIAGSIS AND TREATMENT OF ADULT ASTHMA The purpose of the guideline is to provide an evidence-based summary of the diagnostic management and treatment options available for asthma in the adult population
More informationGuideline topic: Pharmacological management of asthma Evidence table 4.11b: Add-on drugs for inhaled steroids: Long acting or oral B2 agonists
1 of 8 09/05/2018, 11:41 Guideline topic: Pharmacological management of asthma Evidence table 4.11b: Add-on drugs for steroids: Long acting or oral B2 agonists Author Year Study type Quality rating Population
More informationAsthma in the Athlete
Asthma in the Athlete Jorge E. Gomez, MD Associate Professor Texas Children s Hospital Baylor College of Medicine Assist Team Physician UH Understand how we diagnose asthma Objectives Be familiar with
More informationAntileukotrienes and asthma: Alternative or adjunct to inhaled steroids?
CURRENT DRUG THERAPY MANI S. KAVURU, MD Director, Pulmonary Function Laboratory, Department of Pulmonary and Critical Care Medicine, Cleveland Clinic REVATHI SUBRAMONY, RPH Staff Pharmacist, Metrohealth
More informationRespiratory Subcommittee of PTAC meeting held 5 February (minutes for web publishing)
Respiratory Subcommittee of PTAC meeting held 5 February 2010 (minutes for web publishing) Respiratory Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More informationIvax Pharmaceuticals UK Sponsor Submission to the National Institute for Health and Clinical Excellence
Ivax Pharmaceuticals UK Sponsor Submission to the National Institute for Health and Clinical Excellence Clinical and cost-effectiveness of QVAR for the treatment of chronic asthma in adults and children
More informationDATE: 09 December 2009 CONTEXT AND POLICY ISSUES:
TITLE: Tiotropium Compared with Ipratropium for Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease: A Review of the Clinical Effectiveness DATE: 09 December 2009 CONTEXT AND POLICY
More informationRapid Effects of Inhaled Corticosteroids in Acute Asthma Gustavo J. Rodrigo, MD.
Rapid Effects of Inhaled Corticosteroids in Acute Asthma Gustavo J. Rodrigo, MD WWW.chestjournal.org Background: Current reviews on the use of inhaled corticosteroids (ICS) for acute asthma underestimated
More informationComparison of the Effect of Short Course of Oral Prednisone in Patients with Acute Asthma
ISPUB.COM The Internet Journal of Pulmonary Medicine Volume 7 Number 1 Comparison of the Effect of Short Course of Oral Prednisone in Patients with Acute Asthma E Razi, G Moosavi Citation E Razi, G Moosavi.
More informationTreatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark
Asthma and COPD: Are They a Spectrum Treatment Responses Ronald Dahl, Aarhus University Hospital, Denmark Pharmacological Treatments Bronchodilators Inhaled short-acting β -Agonist (rescue) Inhaled short-acting
More informationTREAMENT OF RECURRENT VIRUS-INDUCED WHEEZING IN YOUNG CHILDREN. Dr Lại Lê Hưng Respiratory Department
TREAMENT OF RECURRENT VIRUS-INDUCED WHEEZING IN YOUNG CHILDREN Dr Lại Lê Hưng Respiratory Department Literature review current through: Feb 2013. This topic last updated: Aug 14, 2012 INTRODUCTION Wheezing
More information